1.
N Engl J Med
; 388(6): 565-567, 2023 02 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36630611
Assuntos
COVID-19 , Imunogenicidade da Vacina , Humanos , Anticorpos Neutralizantes , Anticorpos Antivirais , Vacinas Combinadas/imunologia , Vacinas Combinadas/uso terapêutico , Vacinas Sintéticas/imunologia , Vacinas Sintéticas/uso terapêutico , Imunogenicidade da Vacina/imunologia , COVID-19/genética , COVID-19/imunologia , COVID-19/prevenção & controle , COVID-19/virologia , Vacinas de mRNA
2.
bioRxiv
; 2022 Oct 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36324798
RESUMO
Waning immunity following mRNA vaccination and the emergence of SARS-CoV-2 variants has led to reduced mRNA vaccine efficacy against both symptomatic infection and severe disease. Bivalent mRNA boosters expressing the Omicron BA.5 and ancestral WA1/2020 Spike proteins have been developed and approved, because BA.5 is currently the dominant SARS-CoV-2 variant and substantially evades neutralizing antibodies (NAbs). Our data show that BA.5 NAb titers were comparable following monovalent and bivalent mRNA boosters.